AbbVie Maintains Strong Dividend as ABBV Stock Navigates Post-Humira Revenue Transition
AbbVie Inc. remains a core holding for income-focused portfolios as the pharmaceutical giant navigates the revenue transition away from its blockbuster Humira franchise. The company has built a diversified pipeline of immunology, oncology, and neuroscience
AbbVie Maintains Strong Dividend as ABBV Stock Navigates Post-Humira Revenue Transition Read More »
